Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
Menée sur des échantillons tumoraux prélevés sur 40 patients atteints d'un cancer colorectal et 585 patients atteints d'un cancer du poumon non à petites cellules, cette étude évalue la fréquence de deux fusions de gènes, C2orf44-ALK et KIF5B-RET
Applying a next-generation sequencing assay targeting 145 cancer-relevant genes in 40 colorectal cancer and 24 non–small cell lung cancer formalin-fixed paraffin-embedded tissue specimens identified at least one clinically relevant genomic alteration in 59% of the samples and revealed two gene fusions, C2orf44-ALK in a colorectal cancer sample and KIF5B-RET in a lung adenocarcinoma. Further screening of 561 lung adenocarcinomas identified 11 additional tumors with KIF5B-RET gene fusions (2.0%; 95% CI 0.8–3.1%). Cells expressing oncogenic KIF5B-RET are sensitive to multi-kinase inhibitors that inhibit RET.
Nature Medicine 2012